Law360, New York (October 31, 2011, 5:10 PM ET) -- AstraZeneca AB and Pozen Inc. hit Anchen Pharmaceuticals Inc. with a patent infringement lawsuit in New Jersey federal court on Friday in an effort to keep Anchen from launching a generic version of the arthritis drug Vimovo.
AstraZeneca and Pozen, which co-developed Vimovo, claim that Anchen has infringed four patents covering Vimovo by filing an abbreviated new drug application with the U.S. Food and Drug Administration, seeking approval to market its own version of the drug before the patents expire.
Vimovo is a prescription drug approved...
AstraZeneca, Pozen Want Generic Arthritis Drug Blocked
To view the full article, take a free trial now.
